Healthcare Business Review: Geron CEASES Phase 2 Study, Cell Therapeutics JUMPS
Geron Corporation (GERN) ceases its Phase 2 evaluation of imetelstat in HER2-negative breast cancer, due to imetelstat performing worse than the control. In addition, its Phase 2 study of imetelstat for lung cancer is thought unlikely to achieve success.
Don’t Miss: Proctor & Gamble’s Research Woes Take a Toll on Profits.
Zalicus Inc. (ZLCS), subsequent to a Phase 2b trial, says that, “In the absence of a clinically meaningful benefit with Synavive compared to its active glucocorticoid component, Zalicus will discontinue further clinical development with Synavive. These results are not only disappointing to Zalicus, but also to the many steroid-dependent patients who are seeking a safer treatment alternative.”
Shares of biopharmaceutical firm Cell Therapeutics, Inc. (CTIC) gain more than 10 percent Monday, from optimism prior of its Tuesday presentation at the annual Rodman & Renshaw global investment conference. The company is scheduled to discuss the marketing plans for its non-Hodgkin’s lymphoma drug Pixuvri in the European Union, along with an update on the status of clinical trials of pacritinib, which include plans to begin a phase III trial in the fourth quarter.
Nordion Inc. (NDZ) shares collapse on the news that the firm announced plans to suspend its quarterly dividend, due to an arbitration loss linked to claims against Atomic Energy of Canada for the cancelled construction of its MAPLE facilities.
Don’t Miss More Hot Stories by Wall St. Cheat Sheet:
Is Apple’s Stock a BUY at Today’s Price?
Will This Move Help Zynga Win Back Users (And Shareholders)?
This is How Sprint is Preparing for the New iPhone
